Morin et al. (2013)

Summary of novel genes

Entity Total Tier 1 Tier 2 Tier 2 Pass Tier 2 Fail Fail rate
DLBCL 38 9 29 22 7 24%
--- config: sankey: showValues: true linkColor: target width: 600 height: 300 nodeAlignment: right prefix: '(' suffix: ' genes)' --- sankey-beta New to this study, DLBCL Tier 1, 9 New to this study, DLBCL Tier 2, 29 DLBCL Tier 2, Pass QC, 22 DLBCL Tier 2, Fail QC, 7

Novel genes reported in this study

Tier 1

New gene DLBCL tier
CD83 1
CDKN2A 1
GNAI2 1
HIST1H1D 1
HIST1H2AC 1
IKZF3 1
MPEG1 1
RB1 1
TAF1 1

Tier 2

Novel Gene DLBCL Tier Average variant quality QC outcome
ABI3BP 2 ★ ★ ★ ☆ ☆ Pass
CDH9 2 ★ ★ ★ ☆ ☆ Pass
CNTNAP5 2 ★ ★ ★ ★ ☆ Pass
DNAH5 2 ★ ★ ★ ★ ☆ Pass
DSG4 2 ★ ★ ★ ☆ ☆ Pass
FAT4 2 ★ ★ ★ ☆ ☆ Pass
HDAC7 2 ★ ★ ★ ☆ ☆ Pass
HIST1H2AG 2 ★ ★ ★ ☆ ☆ Pass
IFNGR1 2 ★ ★ ★ ★ ☆ Pass
LRRN3 2 ★ ★ ★ ★ ★ Pass
MPDZ 2 ★ ★ ★ ★ ☆ Pass
NLRP5 2 ★ ★ ★ ☆ ☆ Pass
ODZ3 2 ★ ★ ★ ☆ ☆ Pass
P2RX5 2 ★ ★ ★ ☆ ☆ Pass
PASK 2 ★ ★ ★ ★ ☆ Pass
PCDHB11 2 ★ ★ ★ ☆ ☆ Pass
PDS5B 2 ★ ★ ★ ★ ☆ Pass
PRKCB 2 ★ ★ ★ ★ ☆ Pass
SAMD9L 2 ★ ★ ★ ☆ ☆ Pass
SRRM2 2 ★ ★ ★ ☆ ☆ Pass
SYPL1 2 ★ ★ ★ ☆ ☆ Pass
WDFY3 2 ★ ★ ★ ★ ☆ Pass
POGZ 2 ★ ★ ☆ ☆ ☆ Fail
PKD1 2 ★ ★ ☆ ☆ ☆ Fail
IER2 2 ★ ☆ ☆ ☆ ☆ Fail
FAM38B 2 ★ ★ ☆ ☆ ☆ Fail
FNDC1 2 ★ ★ ☆ ☆ ☆ Fail
PTPN23 2 ★ ★ ☆ ☆ ☆ Fail
SARM1 2 ★ ★ ☆ ☆ ☆ Fail

Details

Morin, Ryan D., Karen Mungall, Erin Pleasance, Andrew J. Mungall, Rodrigo Goya, Ryan D. Huff, David W. Scott, et al. 2013. “Mutational and Structural Analysis of Diffuse Large B-cell Lymphoma Using Whole-Genome Sequencing.” Blood 122 (7): 1256–65. https://doi.org/10.1182/blood-2013-02-483727.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

In particular, let us know if you feel that an important citation is missing or if a paper has been cited incorrectly.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.